Dementia and Alzheimer Disease

New research examining the prevalence of chronic traumatic encephalopathy among former NFL players provides additional insight into CTE pathology, while highlighting the challenges of interpreting findings from postmortem brain-donation studies.

Phase 1b/2 findings showed that the investigational anti-amyloid monoclonal antibody ABBV-916 produced dose-dependent reductions in brain amyloid in adults with early Alzheimer disease, although development of the agent was discontinued before dose expansion because of sponsor business considerations.

Here's some of what is coming soon to NeurologyLive® this week.

The FDA has cleared Roche's Elecsys pTau217, a blood test that uses a single biomarker to both rule in and rule out amyloid pathology in adults being evaluated for Alzheimer disease, across both primary and specialty care settings.

Here's some of what is coming soon to NeurologyLive® this week.

FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for adults 40 years and older with cognitive symptoms, offering fast amyloid and tau insight to guide diagnosis and trials in Alzheimer disease.

Kyle Marden, MD, sports neurologist and medical director of the Concussion and Sports Neurology Program at Northwestern Medicine, discusses emerging developments in concussion diagnosis and management, ongoing challenges in the field, and the future of individualized care.

The FDA granted Fast Track designation to Acadia Pharmaceuticals’ investigational remlifanserin for hallucinations and delusions associated with Alzheimer disease psychosis.

Here's some of what is coming soon to NeurologyLive® this week.

A large multicenter study found that APOE genotype and a polygenic Alzheimer risk score together predict up to a 10-year difference in disease onset among people carrying an extra copy of the APP gene, whether through an APP duplication or Down syndrome.

The FDA approved Tauklarify (florquinitau F 18 injection), a tau PET imaging agent, for identifying tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer disease.

Voyager Therapeutics is advancing 2 tau-targeted Alzheimer disease therapies toward key clinical milestones expected in the fourth quarter of 2026, including tau PET imaging data for VY7523 and first-in-human dosing for VY1706.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 7, 2026.

The FDA has granted 510(k) clearance to VoxNeuro's Cognitive Function Neuroimaging software, an EEG/ERP-based tool designed to give clinicians an objective, adjunctive measure of cognitive function.

Neurologist Takaomi Saido, PhD, discusses decades of research into the neprilysin-donanemab and amyloid-beta–tau axes in Alzheimer disease, highlighting potential mechanisms underlying the transition from amyloid to tau pathology and opportunities to develop earlier, more targeted disease-modifying therapies.

Six FDA PDUFA decisions this fall could reshape care in Alzheimer disease, DMD, Sanfilippo syndrome, Alexander disease, and SMA, here's what clinicians need to know about the data behind each.

Catch up on any of the neurology headlines you may have missed in July 2026, compiled into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 31, 2026.

Experts discuss how plasma biomarkers may enable earlier detection of Alzheimer disease pathology, including in cognitively unimpaired individuals and those with subjective cognitive decline, while offering a more accessible alternative to CSF and PET-based assessment. [WATCH TIME: 8 Minutes]

ProMIS Neurosciences reported no cases of ARIA-E in a six-month blinded interim analysis of PMN310, an oligomer-selective antibody in the phase 1b PRECISE-AD trial for Alzheimer disease, alongside early biomarker signals consistent with target engagement.

Phase 1b data published in Nature Medicine and presented at AAIC 2026 showed target engagement and reductions in select cerebrospinal fluid biomarkers of neuronal and synaptic injury with the investigational anti-PD-L1 antibody.

Extended follow-up and new AAIC 2026 data show that tazbentetol, a first-in-class oral synaptic regenerative therapy, produced rapid and durable improvement in cognition and EEG biomarkers in patients with mild-to-moderate Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.